Psychedelic API Market Size, Share, Trends, Growth Outlook

Global Psychedelic API Market Size is valued at $1.9 Billion in 2024 and is forecast to register a growth rate (CAGR) of 12.8% to reach $5 Billion by 2032.

The global Psychedelic API Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Product (API-Grade Psilocybin, API-Grade DMT, LSD API, Ketamine API, Others), By API Compound (Active Plant Components, Novel Synthetic Compounds, Metabolites, Isotopically Labelled Standards), By Source (Natural, Synthetic, Bio-Synthetic), By Grade (GMP, Non-GMP), By Application (Clinical, Research).

An Introduction to Psychedelic API Market in 2024

The Psychedelic API Market in 2024 is emerging as a promising sector in the pharmaceutical industry, driven by increasing research into the therapeutic potential of psychedelic compounds. Active Pharmaceutical Ingredients (APIs) such as psilocybin, LSD, MDMA, and ketamine are being explored for their efficacy in treating mental health conditions like depression, PTSD, anxiety, and addiction. Clinical trials and studies have shown promising results, leading to regulatory approvals and the development of new therapeutic protocols. The market is characterized by advancements in extraction and synthesis methods, ensuring high purity and consistency of psychedelic APIs. As the stigma around psychedelics diminishes and scientific understanding grows, the market for psychedelic APIs is poised for rapid growth, offering new avenues for mental health treatments.

Psychedelic API Market Competitive Landscape

The market report analyses the leading companies in the industry including Atai Life Sciences, Avadel, Beckley Psytech, BetterLife Pharma, Cayman Chemical Company, Celon Pharma SA., Ceruvia Lifesciences LLC, COMPASS Pathways Plc, Core One Labs Inc, Cybin Corp, Entheon Biomedical Corp, F. Hoffmann-La Roche Ltd, Filament Health, GH Research, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals Inc, Jazz Pharmaceuticals Inc, Mindset Pharma, NRx Pharmaceuticals Inc, Pfizer Inc, PharmaTher Holdings Ltd, Psygen Pharmaceutical, Tryp Therapeutics, Verrian, and others.

Psychedelic API Market Dynamics

Psychedelic API Market Trend: Growing Acceptance of Psychedelic Therapies

The prominent trend in the Psychedelic API market is the growing acceptance and recognition of psychedelic therapies for mental health treatment. Psychedelics are being explored for their potential benefits in treating conditions such as depression, PTSD, anxiety, and addiction. Clinical trials and research studies are increasingly demonstrating the therapeutic efficacy of psychedelics, leading to a shift in public perception and regulatory attitudes towards their use in medical settings.

Psychedelic API Market Driver: Increasing Investment in Research and Development

A key driver is the increasing investment in research and development of psychedelic compounds. Pharmaceutical companies, research institutions, and venture capitalists are dedicating significant resources to exploring the therapeutic potential of psychedelics. This investment is driving innovation in drug development, formulation, and delivery methods, accelerating the progress of clinical trials and regulatory approvals, and expanding the market for psychedelic APIs.

Psychedelic API Market Opportunity: Regulatory Advancements and Approvals

An opportunity exists in the regulatory advancements and approvals for psychedelic therapies. As regulatory frameworks evolve and more clinical trials demonstrate the safety and efficacy of psychedelics, there is potential for widespread adoption and commercialization. Countries such as Canada, the United States, and Australia are leading the way in regulatory reform, providing a conducive environment for the development and marketing of psychedelic-based therapies, presenting significant market opportunities for pharmaceutical companies and API manufacturers.

Psychedelic API Market By Product: API-Grade Psilocybin generated the highest revenue in 2024

The largest segment in 2024 for the Psychedelic API market by product is expected to be the API-Grade Psilocybin segment. Psilocybin is gaining significant attention for its potential therapeutic benefits in treating mental health conditions such as depression, anxiety, and PTSD. The growing number of clinical trials and the increasing acceptance of psilocybin-based therapies drive the demand for high-quality API-grade psilocybin, making this segment the largest in the market.

Psychedelic API Market By API Compound: Novel Synthetic Compounds is poised to register the fastest growth over the forecast period to 2032

The segment poised to register the fastest growth to 2030 in the Psychedelic API market by API compound is the Novel Synthetic Compounds segment. The development of novel synthetic psychedelic compounds offers opportunities for creating new and effective treatments for various mental health disorders. The ongoing research and innovation in this field, supported by increasing investments in psychedelic drug development, drive the rapid growth of this segment.

Psychedelic API Market By Source: Synthetic generated the highest revenue in 2024

The largest segment in 2024 for the Psychedelic API market by source is anticipated to be the Synthetic segment. Synthetic psychedelic APIs provide consistent quality, purity, and scalability, essential for pharmaceutical applications. The growing preference for synthetic APIs in clinical research and therapeutic use, due to their controlled production processes, underpins the dominance of this segment in the market.

Psychedelic API Market By Grade: GMP is poised to register the fastest growth over the forecast period to 2032

The segment poised to register the fastest growth to 2030 in the Psychedelic API market by grade is the GMP (Good Manufacturing Practice) segment. The increasing focus on regulatory compliance and the need for high-quality manufacturing standards in the production of psychedelic APIs for clinical trials and therapeutic use drive the demand for GMP-grade APIs. The growing number of companies seeking GMP certification to ensure product safety and efficacy supports the rapid growth of this segment.

Psychedelic API Market

By Product
API-Grade Psilocybin
API-Grade DMT
LSD API
Ketamine API
Others
By API Compound
Active Plant Components
Novel Synthetic Compounds
Metabolites
Isotopically Labelled Standards
By Source
Natural
Synthetic
Bio-Synthetic
By Grade
GMP
Non-GMP
By Application
Clinical
ResearchCountries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Psychedelic API Companies Profiled in the Study

Atai Life Sciences
Avadel
Beckley Psytech
BetterLife Pharma
Cayman Chemical Company
Celon Pharma SA.
Ceruvia Lifesciences LLC
COMPASS Pathways Plc
Core One Labs Inc
Cybin Corp
Entheon Biomedical Corp
F. Hoffmann-La Roche Ltd
Filament Health
GH Research
Hikma Pharmaceuticals PLC
Janssen Pharmaceuticals Inc
Jazz Pharmaceuticals Inc
Mindset Pharma
NRx Pharmaceuticals Inc
Pfizer Inc
PharmaTher Holdings Ltd
Psygen Pharmaceutical
Tryp Therapeutics
Verrian
*- List Not Exhaustive

TABLE OF CONTENTS

1 Introduction to 2024 Psychedelic API Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Psychedelic API Market Size Outlook, $ Million, 2021 to 2032
3.2 Psychedelic API Market Outlook by Type, $ Million, 2021 to 2032
3.3 Psychedelic API Market Outlook by Product, $ Million, 2021 to 2032
3.4 Psychedelic API Market Outlook by Application, $ Million, 2021 to 2032
3.5 Psychedelic API Market Outlook by Key Countries, $ Million, 2021 to 2032

4 Market Dynamics
4.1 Key Driving Forces of Psychedelic API Industry
4.2 Key Market Trends in Psychedelic API Industry
4.3 Potential Opportunities in Psychedelic API Industry
4.4 Key Challenges in Psychedelic API Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Psychedelic API Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Psychedelic API Market Outlook by Segments
7.1 Psychedelic API Market Outlook by Segments, $ Million, 2021- 2032
By Product
API-Grade Psilocybin
API-Grade DMT
LSD API
Ketamine API
Others
By API Compound
Active Plant Components
Novel Synthetic Compounds
Metabolites
Isotopically Labelled Standards
By Source
Natural
Synthetic
Bio-Synthetic
By Grade
GMP
Non-GMP
By Application
Clinical
Research

8 North America Psychedelic API Market Analysis and Outlook To 2032
8.1 Introduction to North America Psychedelic API Markets in 2024
8.2 North America Psychedelic API Market Size Outlook by Country, 2021-2032
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Psychedelic API Market size Outlook by Segments, 2021-2032
By Product
API-Grade Psilocybin
API-Grade DMT
LSD API
Ketamine API
Others
By API Compound
Active Plant Components
Novel Synthetic Compounds
Metabolites
Isotopically Labelled Standards
By Source
Natural
Synthetic
Bio-Synthetic
By Grade
GMP
Non-GMP
By Application
Clinical
Research

9 Europe Psychedelic API Market Analysis and Outlook To 2032
9.1 Introduction to Europe Psychedelic API Markets in 2024
9.2 Europe Psychedelic API Market Size Outlook by Country, 2021-2032
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Psychedelic API Market Size Outlook by Segments, 2021-2032
By Product
API-Grade Psilocybin
API-Grade DMT
LSD API
Ketamine API
Others
By API Compound
Active Plant Components
Novel Synthetic Compounds
Metabolites
Isotopically Labelled Standards
By Source
Natural
Synthetic
Bio-Synthetic
By Grade
GMP
Non-GMP
By Application
Clinical
Research

10 Asia Pacific Psychedelic API Market Analysis and Outlook To 2032
10.1 Introduction to Asia Pacific Psychedelic API Markets in 2024
10.2 Asia Pacific Psychedelic API Market Size Outlook by Country, 2021-2032
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Psychedelic API Market size Outlook by Segments, 2021-2032
By Product
API-Grade Psilocybin
API-Grade DMT
LSD API
Ketamine API
Others
By API Compound
Active Plant Components
Novel Synthetic Compounds
Metabolites
Isotopically Labelled Standards
By Source
Natural
Synthetic
Bio-Synthetic
By Grade
GMP
Non-GMP
By Application
Clinical
Research

11 South America Psychedelic API Market Analysis and Outlook To 2032
11.1 Introduction to South America Psychedelic API Markets in 2024
11.2 South America Psychedelic API Market Size Outlook by Country, 2021-2032
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Psychedelic API Market size Outlook by Segments, 2021-2032
By Product
API-Grade Psilocybin
API-Grade DMT
LSD API
Ketamine API
Others
By API Compound
Active Plant Components
Novel Synthetic Compounds
Metabolites
Isotopically Labelled Standards
By Source
Natural
Synthetic
Bio-Synthetic
By Grade
GMP
Non-GMP
By Application
Clinical
Research

12 Middle East and Africa Psychedelic API Market Analysis and Outlook To 2032
12.1 Introduction to Middle East and Africa Psychedelic API Markets in 2024
12.2 Middle East and Africa Psychedelic API Market Size Outlook by Country, 2021-2032
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Psychedelic API Market size Outlook by Segments, 2021-2032
By Product
API-Grade Psilocybin
API-Grade DMT
LSD API
Ketamine API
Others
By API Compound
Active Plant Components
Novel Synthetic Compounds
Metabolites
Isotopically Labelled Standards
By Source
Natural
Synthetic
Bio-Synthetic
By Grade
GMP
Non-GMP
By Application
Clinical
Research

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
Atai Life Sciences
Avadel
Beckley Psytech
BetterLife Pharma
Cayman Chemical Company
Celon Pharma SA.
Ceruvia Lifesciences LLC
COMPASS Pathways Plc
Core One Labs Inc
Cybin Corp
Entheon Biomedical Corp
F. Hoffmann-La Roche Ltd
Filament Health
GH Research
Hikma Pharmaceuticals PLC
Janssen Pharmaceuticals Inc
Jazz Pharmaceuticals Inc
Mindset Pharma
NRx Pharmaceuticals Inc
Pfizer Inc
PharmaTher Holdings Ltd
Psygen Pharmaceutical
Tryp Therapeutics
Verrian

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
API-Grade Psilocybin
API-Grade DMT
LSD API
Ketamine API
Others
By API Compound
Active Plant Components
Novel Synthetic Compounds
Metabolites
Isotopically Labelled Standards
By Source
Natural
Synthetic
Bio-Synthetic
By Grade
GMP
Non-GMP
By Application
Clinical
Research
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)